Results 261 to 270 of about 435,775 (357)

Learners' Perspectives on Interprofessional Simulation and Co-Debriefing: An Exploratory Mixed-Methods Study. [PDF]

open access: yesJ Nurs Manag
Díaz-Agea JL   +10 more
europepmc   +1 more source

Clinical Factors Associated With Current Relevance in Allergic Contact Dermatitis: Development of Predictive Models Based on Data From the Spanish Contact Dermatitis Register (REIDAC)

open access: yesContact Dermatitis, Volume 94, Issue 6, Page 614-623, June 2026.
This study has shown a moderate performance of the regression model to predict current relevance (AUC = 0.679), although modelling performance has been better for specific allergens (e.g., nickel with an AUC = 0.770). Furthermore, it has identified key predictors, including female gender, specific involved sites (hands, neck, head, legs, feet), and ...
David Pesqué   +31 more
wiley   +1 more source

Social perception, market potential, and ecosystem services valuation of Mediterranean regenerative citrus systems

open access: yesAgronomy Journal, Volume 118, Issue 3, May/June 2026.
Abstract Mediterranean agricultural systems face increasing environmental pressures, including water scarcity, climate variability, and land degradation. Regenerative agriculture has been proposed to enhance sustainability in citrus systems, but its adoption depends on social acceptance and market viability.
Gonzalo Martínez García   +2 more
wiley   +1 more source

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3‐Mutated AML: A FILO‐DATAML‐PETHEMA Real‐World Study

open access: yesAmerican Journal of Hematology, Volume 101, Issue 5, Page 949-960, May 2026.
ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy